Advertisement

Topics

SureSeq Solid Tumour Panel Sequencing Service - Biotech, Pharma and Life Science Channel

06:49 EST 19th February 2017 | BioPortfolio

The SureSeq Solid Tumour Panel Sequencing Service utilises an enrichment panel comprising the full coding regions of 58 prioritised cancer genes. The aim of the panel is to improve cancer care by providing individualised patient profiles facilitating the implementation of personalised treatment strategies. The panel was research-validated for use with fresh, frozen and formalin-fixed, paraffin-embedded (FFPE) samples and focuses on breast, prostate, ovarian, lung and colorectal cancers. OGT also offers the user flexibility to add genes of interest to the panel as part of the service.

The panel was validated against blinded, previously genotyped samples, confirming that the assay accurately detects all variants present. OGT’s expert probe design was found to deliver significantly better uniformity of enrichment than standard design models. A key metric of uniformity, the percentage of bases covered to at least twenty per cent of the mean coverage, increased from 72% in the standard design, to >97.5% in OGT’s current panel.

The assay is optimised to detect low copy variants such as those found in heterogeneous cancer samples so that even low-level changes are classified. The assay called low frequency variants representing between 1% and 2% of bases, at read depths of 600x to 1300x. This feature is enhanced by two factors – firstly the design of the panel and secondly, optimisation of OGT’s Somatic Variant Analysis pipeline to ensure that low-frequency variants are called correctly. OGT’s powerful NGS report provides an integrated end-to-end workflow translating raw results into informed interpretation.

OGT received a funding award of £1.16 million in June 2011 from the UK’s innovation agency, the Technology Strategy Board, as part of a five year programme in stratified medicine research and development involving over £60 million of government funding. Led by OGT, the project is a partnership with the Universities of Southampton and Birmingham, including, West Midlands Regional genetics Laboratory and Birmingham United Molecular Pathology and the Wessex regional Genetics Laboratory and National genetics reference Laboratory in Salisbury.

Another partner in the project, CIS Healthcare develops chemotherapy prescription management software. Results from the tumour profiling assay will be integrated into the Company’s ChemoCare diagnostic module providing clinicians with accurate and up-to-date information on which to base treatment decisions.

Source: http://www.ogt.com/services/805_sureseq_solid_tumour_panel_sequencing_service

News Articles [5 Associated News Articles listed on BioPortfolio]

Oxford Gene Technology Ltd Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250

SummaryOxford Gene Technology Ltd OGT is a biotechnology company that develops biomarkers. The company offers automation products, chromosomespecific arrays, custom arrays, fish probes, genefocused ar...

OGT Releases Targeted NGS Panel to Study SNV and CNV in Familial Hypercholesterolemia

OXFORD, England, December 8, 2016 /PRNewswire/ -- Oxford Gene Technology (OGT), The Molecular Genetics Company, has expanded its customisable SureSeq™ NGS panel range with the launch of the Sure...

OGT Announces Commercial and Financial Highlights for FY 2016

OXFORD, England, November 22, 2016 /PRNewswire/ --  Highly integrated molecular genetics portfolio delivers significant revenue growth and sustainable profit  Oxford Gene Technology ...

OGT Simplifies Detection of Important Cancer Gene Variants

OXFORD, England, September 27, 2016 /PRNewswire/ -- Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched its SureSeq myPanel™ NGS Custom Cancer Panels to provide scientist...

OGT Expands Cytocell FISH Probe Portfolio for Lung Cancers

OXFORD, England, September 13, 2016 /PRNewswire/ -- New probes facilitate diagnosis and stratified treatment of NSCLC  Oxford Gene Technology (OGT), The Molecular Genetics Company, has launched...

Events [0 Results]

None

Companies [0 Results]

None

Clinical Trials [0 Results]

None

PubMed Articles [0 Results]

None

Videos

None available.

Medical and Biotech [MESH] Definitions

None available.

Quick Search
Advertisement
 

Relevant Topics

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

review and buy SureSeq Solid Tumour Panel Sequencing Service market research data and corporate reports here

Channels Quicklinks